Sen. Grassley comments on newly released JAMA articles and commentary regarding Avandia
Sen. Chuck Grassley issued the comment below regarding the analysis released today by JAMA, the Journal of the American Medical Association, regarding the safety of the diabetes drug Avandia. Sen. Grassley has conducted active oversight since 2004 of the drug safety program of the Food and Drug Administration. He has documented and sought legislative reforms to address the agency’s too-cozy relationship with the pharmaceutical industry and its reactive rather than proactive approach to post-market surveillance of pharmaceutical drugs.
“This analysis and commentary sums up a case study in what’s wrong with the drug safety system inside the FDA. From drug approval to post-market surveillance, FDA reform is important, because public safety is at stake. Above all, FDA leaders need to adhere to the scientific process and use an even-handed approach with drug-safety deliberations. The FDA’s relationship with drug makers is too cozy and is costing the agency its credibility and the public’s confidence.”
###
Next Article Previous Article
Recent News
- Wyden Sounds the Alarm on DOGE Accessing Social Security Systems Containing Americans’ Sensitive Personal and Financial Information
- Democratic Health Leaders Call for Inspector General Investigation into Elon Musk’s Access to Americans’ Sensitive Health Care information
- Responding to Evidence of a Treasury Cover-Up, Wyden Demands Bessent Come Clean on Musk Infiltration of Treasury Payment Systems
- Wyden Statement on Senate Republican Budget Resolution
- Wyden Opening Statement on Nomination of Jamieson Greer for US Trade Representative